William Blair analyst Andy Hsieh has maintained their bullish stance on VKTX stock, giving a Buy rating on July 24.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andy Hsieh has given his Buy rating due to a combination of factors that highlight Viking Therapeutics’ promising position in the pharmaceutical industry. The company’s obesity franchise is seen as particularly attractive, offering unique qualities that could appeal to larger pharmaceutical companies considering mergers and acquisitions. This is largely due to the potential of VK2735, which is available in both oral and subcutaneous forms, and the added flexibility provided by the dual amylin and calcitonin receptor agonist program.
Furthermore, the interest in the direct-to-consumer market provides Viking Therapeutics with multiple opportunities for success, independent of any acquisition scenarios. The anticipation surrounding the upcoming Phase II data release for the oral formulation of VK2735, expected in the latter half of the year, further supports this optimistic outlook. Viking Therapeutics has been previously identified as a top pick for 2025, reinforcing the confidence in its future performance.
In another report released on July 24, H.C. Wainwright also reiterated a Buy rating on the stock with a $102.00 price target.
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VKTX in relation to earlier this year.